Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...

Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and ...

Teva Pharmaceuticals TEVA announced a funding agreement with Royalty Pharma plc RPRX, under which the latter will provide up ...

Teva Pharmaceutical Industries (TASE: TEVA; NYSE: TEVA) published two positive announcements yesterday. The first concerns ...

Royalty Pharma and the US affiliate of Israel’s Teva Pharmaceutical Industries have announced a funding agreement of up to ...

The Food and Drug Administration has approved Teva’s Ajovy for the preventive treatment of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or ...

A federal judge denied Teva's bid to delay the first Paragard bellwether trial, keeping a January start date for claims tied ...

Teva Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration for the first generic GLP-1 medication for weight loss, the Parsippany-based company announced Aug. 28. The ...

Shares of Teva Pharmaceutical Industries Ltd. climbed Monday in the first trading day after a federal court reaffirmed patents protecting the drugmaker's biggest brand-name product, the multiple ...

Product: All strengths of Teva Octreotide for Injectable Suspension Kit (DIN 02503751, 02503778 and 0253786) with the lot numbers noted below. Issue: Health products – Product quality What to do: If ...

Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population 1 Olanzapine LAI is designed ...